ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / RADX / news
AEON (46) KPTI (29) MRKR (35) NEUP (31) ⌘ Pro Terminal →

Why RADX Stock dropped -8.05% Today — RQD Quant Desk Flash

$0.99 -8.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.97

Radiopharm Theranostics Limited (RADX) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $15.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RADX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RADX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Radiopharm Theranostics Limited (NASDAQ: RADX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $0.99 (-8.05% 1D, market cap $15.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, RADX ranks #345 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RADX compare to AEON and KPTI in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RADX carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AEON (AEON Biopharma Inc. (Class A)) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $16.2M) and KPTI (Karyopharm Therapeutics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $15.0M). Among the 5-stock peer group, RADX leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RADX?
▼

For Radiopharm Theranostics Limited (RADX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #345 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.97 (-1.64%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510046
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D+
Cash (12)Whales (3)SEC (13)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.1% Base Target
$17 Bull$1 Base$1 Bear
📬 FREE RADX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RADX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY RADX SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($437.2K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
54
Grade C-$1.20-17.5% Next Q
Q2 (-2Q)
51
Grade C-$0.99-9.1% Next Q
Q3 (-1Q)
49
Grade D$0.90+10% Next Q
Current
46
Grade D$0.99-6.1% Hist 90D α
Trajectory: C- (54) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RADX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RADX currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.53) and Max Pain ($1.04) forces dealer call-delta covering toward $17.06.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RADX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RADX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 46%NO 54%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why RADX Stock dropped -8.05% Today — RQD Quant Desk Flash

Radiopharm Theranostics Limited (RADX) dropped -8.05% to $0.99, trading at 2% of its 52-week range ($0.9 – $16.25). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 2% of its 52-week range ($0.9 – $16.25) with RSI-14 at 41.7 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.99 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $437225 annual free cash flow.
Live RADX Headlines & Catalysts
MARKET WIREBenzinga • 11d ago
12 Health Care Stocks Moving In Friday's After-Market Session

Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares rose 8.72% to

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RADX)

  • ✓Walkthrough of RADX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RADX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -78.00%▼ DESCENDING CHANNEL
2026-11-03O $1.12H $1.12L $0.99C $0.99VOL 8.9K
RES: $3.56SUP: $0.27SMA50: $1.53SMA200: $3.63
$5.47$4.23$2.99$1.75$0.52RES $3.56SUP $0.27$0.992026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RADX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RADX Butterfly Map → + Track RADX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RADX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RADX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RADX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RADX)

Health Care Rank #345 of 1015 ⚔️ AEON vs RADX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RADX vs. AEON, KPTI, MRKR, NEUP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Radiopharm Theranostics Limited (RADX) ranks #345 by composite RQD confidence (46/100, grade D) and #850 by equity capitalization ($15.6M). Within this direct 5-issuer industry benchmark cohort, RADX leads on earnings valuation at N/A trailing P/E, while NEUP leads on capital efficiency and profitability with -11.8% ROIC and — gross margin. RADX currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RADX ACTIVE
Radiopharm Theranostics Limited
D 46/100 — — — -8.05% $15.6M Benchmark Subject
AEON
AEON Biopharma Inc. (Class A)
D 46/100 — — -35.0% -0.36% $16.2M /aeon-vs-radx →
KPTI
Karyopharm Therapeutics Inc.
E 29/100 — — -35.0% -83.08% $15.0M /kpti-vs-radx →
MRKR
Marker Therapeutics Inc.
D- 35/100 — — -35.0% -8.05% $16.3M /mrkr-vs-radx →
NEUP
Neuphoria Therapeutics Inc.
E 31/100 — — -11.8% -0.33% $16.5M /neup-vs-radx →

2. RADX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Radiopharm Theranostics Limited (RADX) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $15.6M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. RADX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RADX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Radiopharm Theranostics Limited (NASDAQ: RADX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $0.99 (-8.05% 1D, market cap $15.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, RADX ranks #345 in composite RQD confidence.

How does RADX compare to AEON and KPTI in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RADX carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AEON (AEON Biopharma Inc. (Class A)) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $16.2M) and KPTI (Karyopharm Therapeutics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $15.0M). Among the 5-stock peer group, RADX leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RADX?

For Radiopharm Theranostics Limited (RADX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #345 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RADX trading relative to its 50-day, 200-day, and 52-week technical levels?

RADX last traded at $0.99 (-8.05% on volume of 38,312 shares), positioning the stock -35.29% below its 50-day simple moving average ($1.53) and -72.73% below its 200-day simple moving average ($3.63). Across its 52-week range of $0.90 to $16.25, RADX sits at the 0.6% percentile with a 14-day RSI of 41.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.11).

Direct Sub-Reports: RADX RQD Cockpit RADX 12M Forecast RADX Earnings & Move RADX Dividends & DRIP RADX Insiders & 13F RADX Whale Options RADX Profit Sankey RADX News & Why
ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ SEC XBRL & RQD VERIFIED

RADX — Radiopharm Theranostics Limited: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Radiopharm Theranostics Limited (RADX) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $0.99 (-8.05% 1D, market capitalization $15.6M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Radiopharm Theranostics Limited is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The profile identifies the company as a biotechnology issuer with a market capitalization of $0.0B. Recent headlines reference a brain imaging agent, RAD101, and an end-of-Phase 2 meeting with the U.S. Food and Drug Administration for its pivotal development program.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 46/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.90 – $16.25 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The sector classification is Health Care and the industry is Biotechnology: Pharmaceutical Preparations. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are — The only sector-level input in the source data is the beta of 1.0 from the market data, which the RQD rating scores as sector sensitivity under Macro Regime Fit.

  • Key Question #1: Can RADX sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $16.25 52-week high?
  • Key Question #3: How sensitive is RADX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

RADX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Radiopharm Theranostics Limited (RADX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RADX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RADX Bull vs. Bear Conversation Board — What's Your Call at $0.99?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RADX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on RADX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $1.24 (+14.8%)
📌 Pinned Debate

Headlines report a productive end-of-Phase 2 FDA meeting for the pivotal RAD101 program, a potential clinical catalyst.

Headlines report a productive end-of-Phase 2 FDA meeting for the pivotal RAD101 program, a potential clinical catalyst.. When you look under the hood at RADX, Fundamental Cash Engine is 12/20 with 0.0% gross margins and 0.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $16.25. My 12M target is $1.24.

EarningsSniper 🐂 BULL

Both sides have a point here — RADX's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $0.83 (-23.1%)
Spot @ $1.08

The RQD scores ROIC and FCF yield at 0% and institutional flow at 3 of 20, with headlines citing A$10.7M quarterly cash use.

The RQD scores ROIC and FCF yield at 0% and institutional flow at 3 of 20, with headlines citing A$10.7M quarterly cash use.. Look at the math on RADX: paying current EV/EBITDA multiples for 0.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $0.95 before getting long.

LIVE TAPE